Brief: Novartis To Buy Tourmaline Bio
09/09/2025 06:05
Sept 9 (Reuters) - NOVARTIS AG NOVN.S: TO ACQUIRE TOURMALINE BIO, COMPLEMENTING CARDIOVASCULAR PIPELINE WITH PACIBEKITUG FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) OFFER PRICE USD 48 PER SHARE, COMPANY VALUED AT USD 1.4BN EXPECTS TO MERGE ACQUIRING SUBSIDIARY WITH AND INTO TOURMALINE TRANSACTION IS EXPECTED TO CLOSE IN Q4 OF 2025 Source text: ID:nGNE7bpPpy Further company coverage: NOVN.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Tourmaline Bio
See all newsBrief: Novartis Completes Acquisition Of Tourmaline Bio
Brief: Novartis Announces Expiration Of Tourmaline Bio Tender Offer
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports (updated)
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy